MAP2K7 and Familial prostate cancer: The synergistic application of AZD8186 alongside Selumetinib (a MEK/ERK pathway inhibitor) resulted in diminished cell proliferation and heightened apoptosis in docetaxel-resistant metastatic castration-resistant prostate cancer cells that express PTEN.